OOIR: Observatory of International Research

Papers

(The median citation count of Journal of the American College of Cardiology is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019	4200
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up	2084
Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic	1271
Reduction in ST-Segment Elevation Cardiac Catheterization Laboratory Activations in the United States During COVID-19 Pandemic	871
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease	805
Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19	728
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure	726
2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction	564
2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization	513
Prevalence and Impact of Myocardial Injury in Patients Hospitalized With COVID-19 Infection	510
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary	508
STS-ACC TVT Registry of Transcatheter Aortic Valve Replacement	488
Valve Academic Research Consortium 3: Updated Endpoint Definitions for Aortic Valve Clinical Research	397
Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19	355
2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy	348
Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation	333
The Global Burden of Cardiovascular Diseases and Risk	325
2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain	319
Cardiac Troponin for Assessment of Myocardial Injury in COVID-19	300
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary	295
Saturated Fats and Health: A Reassessment and Proposal for Food-Based Recommendations	290
Worldwide Prevalence of Familial Hypercholesterolemia	287
Catheterization Laboratory Considerations During the Coronavirus (COVID-19) Pandemic	285
Preeclampsia—Pathophysiology and Clinical Presentations	281
Characterization of Myocardial Injury in Patients With COVID-19	277

Virtual Learning During the COVID-19 Pandemic	266
2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes	262
Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction	256
Inflammation in Heart Failure	252
The Global Burden of Cardiovascular Diseases and Risks	247
Fewer Hospitalizations for Acute Cardiovascular Conditions During the COVID-19 Pandemic	244
Transcatheter Edge-to-Edge Repair for Treatment of Tricuspid Regurgitation	240
Remnant Cholesterol, Not LDL Cholesterol, Is Associated With Incident Cardiovascular Disease	229
The NCDR Left Atrial Appendage Occlusion Registry	228
Registry of Arterial and Venous Thromboembolic Complications in Patients With COVID-19	220
Management of Acute Myocardial Infarction During the COVID-19 Pandemic	216
Interpreting the Kansas City Cardiomyopathy Questionnaire in Clinical Trials and Clinical Care	214
2022 ACC Expert Consensus Decision Pathway on Cardiovascular Sequelae of COVID-19 in Adults: Myocarditis and Other Myocardial Involvement, Post-Acute Sequelae of SARS-CoV-2 Infection, and Return to Pl	209
Spontaneous Coronary Artery Dissection	206
High Thrombus Burden in Patients With COVID-19 Presenting With ST-Segment Elevation Myocardial Infarction	205
Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy	204
Biological Versus Chronological Aging	203
Intravascular Lithotripsy for Treatment of Severely Calcified Coronary Artery Disease	202
SCAI SHOCK Stage Classification Expert Consensus Update: A Review and Incorporation of Validation Studies	200
Association of Age of Onset of Hypertension With Cardiovascular Diseases and Mortality	196
Mobile Health Technology to Improve Care for Patients With Atrial Fibrillation	196
Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk	195
Atrial Dysfunction in Patients With Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation	194
Coronary Microvascular Dysfunction Across the Spectrum of Cardiovascular Diseases	192
Alzheimer’s Disease and Vascular Aging	190
The ARIC (Atherosclerosis Risk In Communities) Study	189
Sleep Irregularity and Risk of Cardiovascular Events	186
Machine Learning and the Future of Cardiovascular Care	182
Incidence and Long-Term Outcomes of Hypertensive Disorders of Pregnancy	182
2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants	180
Primary and Secondary Prevention of Ischemic Stroke and Cerebral Hemorrhage	180
Prevalence and Outcomes of Concomitant Aortic Stenosis and Cardiac Amyloidosis	177
Wearable Devices for Ambulatory Cardiac Monitoring	176
Echocardiographic Findings in Pediatric Multisystem Inflammatory Syndrome Associated With COVID-19 in the United States	174
Pathological Evidence for SARS-CoV-2 as a Cause of Myocarditis	172
Randomized Trial of Interleukin-6 Receptor Inhibition in Patients With Acute ST-Segment Elevation Myocardial Infarction	167
Management and Outcomes of Patients With STEMI During the COVID-19 Pandemic in China	167
Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women	166
Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy	165
Subclinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Valves	161
Pulsed Field Ablation in Patients With Persistent Atrial Fibrillation	160
Triglyceride-Rich Lipoprotein Cholesterol, Small Dense LDL Cholesterol, and Incident Cardiovascular Disease	155
Diuretic Therapy for Patients With Heart Failure	150
Coronavirus and Cardiovascular Disease, Myocardial Injury, and Arrhythmia	150
Time Course of LDL Cholesterol Exposure and Cardiovascular Disease Event Risk	149
Prognostic Impact of Prior Heart Failure in Patients Hospitalized With COVID-19	149
Heart Failure With Recovered Left Ventricular Ejection Fraction	146
Cardiovascular Deaths During the COVID-19 Pandemic in the United States	146
Diagnosis and Evaluation of Hypertrophic Cardiomyopathy	146
Impact of Plaque Burden Versus Stenosis on Ischemic Events in Patients With Coronary Atherosclerosis	144

Impact of COVID-19 Pandemic on Mechanical Reperfusion for Patients With STEMI	144
Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19	143
2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary	142
Ventricular Arrhythmias in Myocarditis	142
Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients	140
2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia	139
2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary	139
Validation of the Academic Research Consortium High Bleeding Risk Definition in Contemporary PCI Patients	138
2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk	137
Coronary Computed Tomography Angiography From Clinical Uses to Emerging Technologies	135
Feasibility Study of the Transcatheter Valve Repair System for Severe Tricuspid Regurgitation	135
Bicuspid Aortic Valve Morphology and Outcomes After Transcatheter Aortic Valve Replacement	133
2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or Wi	132
Repeat Transcatheter Aortic Valve Replacement for Transcatheter Prosthesis Dysfunction	131
Mechanisms of Vascular Aging, A Geroscience Perspective	130
International Impact of COVID-19 on the Diagnosis of Heart Disease	127
2020 Focused Update of the 2017 ACC Expert Consensus Decision Pathway on the Management of Mitral Regurgitation	126
Bioprosthetic Aortic Valve Leaflet Thickening in the Evolut Low Risk Sub-Study	125
Cardiac Scintigraphy With Technetium-99m-Labeled Bone-Seeking Tracers for Suspected Amyloidosis	125
Management of Hypertrophic Cardiomyopathy	124
Percutaneous Coronary Intervention for Vulnerable Coronary Atherosclerotic Plaque	122
Pathophysiology of Takotsubo Syndrome	122
Randomized Trial of Left Bundle Branch vs Biventricular Pacing for Cardiac Resynchronization Therapy	119
Dietary Inflammatory Potential and Risk of Cardiovascular Disease Among Men and Women in the U.S.	118
Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis	118
Presentation and Outcome of Arrhythmic Mitral Valve Prolapse	117
Baroreflex Activation Therapy in Patients With Heart Failure With Reduced Ejection Fraction	116
Clinical Implications of SARS-CoV-2 Interaction With Renin Angiotensin System	116
Antithrombotic Therapy for Patients With Left Ventricular Mural Thrombus	116
Ticagrelor With or Without Aspirin After Complex PCI	115
2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease	113
Atrial Fibrillation	112
3-Year Outcomes of Transcatheter Mitral Valve Repair in Patients With Heart Failure	112
Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy	111
Multiple Plasma Biomarkers for Risk Stratification in Patients With Heart Failure and Preserved Ejection Fraction	111
Recurrence of Atrial Fibrillation After Catheter Ablation or Antiarrhythmic Drug Therapy in the CABANA Trial	111
Challenges in Cardiac and Pulmonary Sarcoidosis	110
Structural Deterioration of Transcatheter Versus Surgical Aortic Valve Bioprostheses in the PARTNER-2 Trial	110
Prevalence and Prognostic Significance of Malnutrition in Patients With Acute Coronary Syndrome	109
Therapeutic Potential of Ketone Bodies for Patients With Cardiovascular Disease	109
Global Chronic Total Occlusion Crossing Algorithm	108
Post-Stroke Cardiovascular Complications and Neurogenic Cardiac Injury	108
Smartphone Activation of Citizen Responders to Facilitate Defibrillation in Out-of-Hospital Cardiac Arrest	108
Clonal Hematopoiesis and Risk of Progression of Heart Failure With Reduced Left Ventricular Ejection Fraction	108
Inhibition of Interleukin-1β and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial	107
Short-Term Exposure to Ambient Air Pollution and Mortality From Myocardial Infarction	107
4-Year Outcomes After Left Atrial Appendage Closure Versus Nonwarfarin Oral Anticoagulation for Atrial Fibrillation	105
Interventions for Frailty Among Older Adults With Cardiovascular Disease	105
Inflammation, Aging, and Cardiovascular Disease	104
Medial Arterial Calcification	101
Cardiac Involvement in Fabry Disease	101
Associations Between Cardiovascular Risk, Structural Brain Changes, and Cognitive Decline	101
Epicardial Adipose Tissue Accumulation Confers Atrial Conduction Abnormality	101
Trends and Outcomes of Restenosis After Coronary Stent Implantation in the United States	101
Predictors of Device-Related Thrombus Following Percutaneous Left Atrial Appendage Occlusion	100
VLDL Cholesterol Accounts for One-Half of the Risk of Myocardial Infarction Associated With apoB-Containing Lipoproteins	100
Atherosclerotic Carotid Plaque Composition and Incident Stroke and Coronary Events	100
ASE Statement on Protection of Patients and Echocardiography Service Providers During the 2019 Novel Coronavirus Outbreak	99
Management of Intracerebral Hemorrhage	99
Mitochondria-Rich Extracellular Vesicles From Autologous Stem Cell–Derived Cardiomyocytes Restore Energetics of Ischemic Myocardium	99
Primary Aldosteronism in Patients in China With Recently Detected Hypertension	98
Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure	98
Ultra-Processed Foods and Incident Cardiovascular Disease in the Framingham Offspring Study	97
Cardiac Rehabilitation for Patients With Heart Failure	97
Type A Aortic Dissection—Experience Over 5 Decades	97
Sleep Disordered Breathing and Cardiovascular Disease	95
Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction	95
Association of Clonal Hematopoiesis With Incident Heart Failure	95
Coronary 18F-Sodium Fluoride Uptake Predicts Outcomes in Patients With Coronary Artery Disease	95
Takotsubo Cardiomyopathy in COVID-19	95
The Alzheimer’s Disease Amyloid-Beta Hypothesis in Cardiovascular Aging and Disease	94
2020 ACC Expert Consensus Decision Pathway on Management of Conduction Disturbances in Patients Undergoing Transcatheter Aortic Valve Replacement	93
Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor–Associated Myocarditis	92
Comparative Trends in Percutaneous Coronary Intervention in Japan and the United States, 2013 to 2017	92
Early Diagnosis of Myocardial Infarction With Point-of-Care High-Sensitivity Cardiac Troponin I	91
Transcatheter Valve-in-Valve Aortic Valve Replacement as an Alternative to Surgical Re-Replacement	91
Right Ventricular-Pulmonary Arterial Coupling and Afterload Reserve in Patients Undergoing Transcatheter Tricuspid Valve Repair	91
Trajectories of Age-Related Arterial Stiffness in Chinese Men and Women	91
Drug-Coated Balloon for De Novo Coronary Artery Disease	90
Safety of Transesophageal Echocardiography to Guide Structural Cardiac Interventions	90

Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload	90
Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers	90
Initial Findings From the North American COVID-19 Myocardial Infarction Registry	89
Simultaneous Endocardial and Epicardial Delineation of 3D Reentrant Ventricular Tachycardia	89
Management and Outcomes of Cardiogenic Shock in Cardiac ICUs With Versus Without Shock Teams	88
Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia	88
Transcatheter Mitral Valve Therapy in the United States	87
Penetrance of Hypertrophic Cardiomyopathy in Sarcomere Protein Mutation Carriers	87
Abnormalities of Potassium in Heart Failure	87
Incorporating Coronary Calcification Into Pre-Test Assessment of the Likelihood of Coronary Artery Disease	86
Mortality in Patients With Atrial Fibrillation Receiving Nonrecommended Doses of Direct Oral Anticoagulants	86
Kidney Function and Outcomes in Patients Hospitalized With Heart Failure	86
Emerging RNA Therapeutics to Lower Blood Levels of Lp(a)	86
Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment	86
Drug-Coated Balloon Angioplasty Versus Drug-Eluting Stent Implantation in Patients With Coronary Stent Restenosis	85
Select Drug-Drug Interactions With Direct Oral Anticoagulants	85
Prognostic Utility of Right Ventricular Remodeling Over Conventional Risk Stratification in Patients With COVID-19	84
Exercise Intolerance in Older Adults With Heart Failure With Preserved Ejection Fraction	84
2-Year Outcomes of Transcatheter Mitral Valve Replacement in Patients With Severe Symptomatic Mitral Regurgitation	83
2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis	81
Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension	80
Olive Oil Consumption and Cardiovascular Risk in U.S. Adults	80
Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction	79
Electronic Alerts to Improve Heart Failure Therapy in Outpatient Practice	79
Cardiovascular Disease Projections in the United States Based on the 2020 Census Estimates	79
Triglycerides and Residual Atherosclerotic Risk	79
Limitations of Contemporary Guidelines for Managing Patients at High Genetic Risk of Coronary Artery Disease	78
Improved Risk Stratification for Ventricular Arrhythmias and Sudden Death in Patients With Nonischemic Dilated Cardiomyopathy	78
Prognostic Value of Magnetic Resonance Phenotype in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy	77
Mechanical Left Ventricular Unloading in Patients Undergoing Venoarterial Extracorporeal Membrane Oxygenation	77
Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF	76
Global Burden of Cardiovascular Diseases and Risks Collaboration, 1990-2021	75
Team-Based Care of Women With Cardiovascular Disease From Pre-Conception Through Pregnancy and Postpartum	75
AntimiR-21 Prevents Myocardial Dysfunction in a Pig Model of Ischemia/Reperfusion Injury	75
Renal Denervation in High-Risk Patients With Hypertension	75
High Prevalence of Deep Vein Thrombosis in Mechanically Ventilated COVID-19 Patients	74
International Prospective Registry of Acute Coronary Syndromes in Patients With COVID-19	74
Factor XI Inhibition to Uncouple Thrombosis From Hemostasis	73
Practice Changes at U.S. Transplant Centers After the New Adult Heart Allocation Policy	73
Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes	73
Substrate Ablation vs Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia	73
Evaluation for Heart Transplantation and LVAD Implantation	73
Implications of Alternative Definitions of Peri-Procedural Myocardial Infarction After Coronary Revascularization	71
Pulmonary Hypertension in HFpEF and HFrEF	71
Menopause-Related Estrogen Decrease and the Pathogenesis of HFpEF	71
Impact of Peri-Procedural Myocardial Infarction on Outcomes After Revascularization	70
Targeting Cyclic Guanosine Monophosphate to Treat Heart Failure	70
Validation of a Genome-Wide Polygenic Score for Coronary Artery Disease in South Asians	70
Myocardial Bridging: Diagnosis, Functional Assessment, and Management	69
Meta-Analysis of Reversal Agents for Severe Bleeding Associated With Direct Oral Anticoagulants	69
Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF	68
Coronary In-Stent Restenosis	68
Association of Cumulative Blood Pressure With Cognitive Decline, Dementia, and Mortality	68
Transcatheter Correction of Superior Sinus Venosus Atrial Septal Defects as an Alternative to Surgical Treatment	68
Criteria for Iron Deficiency in Patients With Heart Failure	67
Cardiopulmonary Impact of Particulate Air Pollution in High-Risk Populations	67
Physiological Stratification of Patients With Angina Due to Coronary Microvascular Dysfunction	67
Prognostic Implications of Declining Hemoglobin Content in Patients Hospitalized With Acute Coronary Syndromes	67
Phase-III Clinical Trial of Fluorine-18 Flurpiridaz Positron Emission Tomography for Evaluation of Coronary Artery Disease	67
Prospective Evaluation of Autonomic Dysfunction in Post-Acute Sequela of COVID-19	67
Associations of Late Adolescent or Young Adult Cardiovascular Health With Premature Cardiovascular Disease and Mortality	66
Long-Term Outcomes in Women and Men Following Percutaneous Coronary Intervention	66
Criteria for Defining Stages of Cardiogenic Shock Severity	66
Managing Atherosclerotic Cardiovascular Risk in Young Adults	66
Individualized Nutritional Support for Hospitalized Patients With Chronic Heart Failure	66
Survival After Coronary Revascularization With Paclitaxel-Coated Balloons	66
Propensity-Matched Comparison of the Ross Procedure and Prosthetic Aortic Valve Replacement in Adults	65
Cardiopulmonary Hemodynamics in Pulmonary Hypertension and Heart Failure	65
Association of Lipoprotein(a) With Atherosclerotic Plaque Progression	65
2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction	64
Discrepancies in Measurement of the Thoracic Aorta	64
Coronary Computed Tomographic Angiography for Complete Assessment of Coronary Artery Disease	64
Systolic Blood Pressure Time in Target Range and Cardiovascular Outcomes in Patients With Hypertension	63
Microvascular Resistance Reserve for Assessment of Coronary Microvascular Function	63
Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol	62
Transcatheter Replacement of Transcatheter Versus Surgically Implanted Aortic Valve Bioprostheses	62
Eruptive Calcified Nodules as a Potential Mechanism of Acute Coronary Thrombosis and Sudden Death	62
Complicated Carotid Artery Plaques as a Cause of Cryptogenic Stroke	62
Impact of Tricuspid Regurgitation on Clinical Outcomes	62
African-American COVID-19 Mortality	61
Timing of Oral P2Y12 Inhibitor Administration in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome	61
Proteomic Signatures of Heart Failure in Relation to Left Ventricular Ejection Fraction	60
Long-Term Adverse Cardiac Outcomes in Patients With Sarcoidosis	60
Gerotechnology for Older Adults With Cardiovascular Diseases	60
Hypertensive Disorders of Pregnancy and Subsequent Risk of Premature Mortality	60
Changes in Plasma Renin Activity After Renal Artery Sympathetic Denervation	60
Increasing Participation of Women in Cardiovascular Trials	59
Cardiovascular Risk in Patients With Psoriasis	59
Reliability of Office, Home, and Ambulatory Blood Pressure Measurements and Correlation With Left Ventricular Mass	59
High-Sensitivity C-Reactive Protein Modifies the Cardiovascular Risk of Lipoprotein(a)	59
Long-Term Outcomes of Patients Undergoing the Ross Procedure	59
Randomized Trial of Ivabradine in Patients With Hyperadrenergic Postural Orthostatic Tachycardia Syndrome	59
Acute Myocardial Injury at Hospital Admission Is Associated With All-Cause Mortality in COVID-19	59
Diet-Derived Circulating Antioxidants and Risk of Coronary Heart Disease	58
Independent Association of Lipoprotein(a) and Coronary Artery Calcification With Atherosclerotic Cardiovascular Risk	58